4DMedical (4DX) Stock Overview
Operates as a medical technology company in the United States and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
4DX Community Fair Values
Create NarrativeSee what 55 others think this stock is worth. Follow their fair value or set your own to get alerts.
4DMedical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$5.34 |
| 52 Week High | AU$7.55 |
| 52 Week Low | AU$0.23 |
| Beta | 2.21 |
| 1 Month Change | 24.19% |
| 3 Month Change | 20.27% |
| 1 Year Change | 1,877.78% |
| 3 Year Change | 567.50% |
| 5 Year Change | 236.91% |
| Change since IPO | 235.85% |
Recent News & Updates
Recent updates
Acquisitions, Philips Partnerships And FDA Approvals Will Expand Market Reach
Strategic acquisitions, partnerships, and regulatory approvals are poised to enhance market presence, revenue, and net margins through expanded distribution and high-margin services.Here's Why We're Watching 4DMedical's (ASX:4DX) Cash Burn Situation
Sep 21
We're Keeping An Eye On 4DMedical's (ASX:4DX) Cash Burn Rate
May 084DMedical Limited's (ASX:4DX) CEO Compensation Is Looking A Bit Stretched At The Moment
Oct 26Here's Why We're Not At All Concerned With 4DMedical's (ASX:4DX) Cash Burn Situation
Jun 16We Think 4DMedical (ASX:4DX) Needs To Drive Business Growth Carefully
Feb 01Is 4DMedical (ASX:4DX) In A Good Position To Deliver On Growth Plans?
Oct 18Shareholder Returns
| 4DX | AU Healthcare Services | AU Market | |
|---|---|---|---|
| 7D | -15.4% | 9.0% | 0.8% |
| 1Y | 1,877.8% | -25.7% | 14.1% |
Return vs Industry: 4DX exceeded the Australian Healthcare Services industry which returned -25.7% over the past year.
Return vs Market: 4DX exceeded the Australian Market which returned 14.1% over the past year.
Price Volatility
| 4DX volatility | |
|---|---|
| 4DX Average Weekly Movement | 16.3% |
| Healthcare Services Industry Average Movement | 11.9% |
| Market Average Movement | 10.7% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 4.6% |
Stable Share Price: 4DX's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: 4DX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 124 | Andreas Fouras | 4dmedical.com |
4DMedical Limited operates as a medical technology company in the United States and Australia. The company engages in the medical research technology and development of a non-invasive respiratory imaging solution using four-dimensional imaging. It offers CT:VQ, non contrast post processing technology; CAC, a non-contrast cardiothoracic risk assessment sotware; CT LVAS, a regional lung function imaging software; IQ-UIP, a state-of-the-art software; LDAf, Patented Parametric Response Mapping (PRM) technology; LDAi, an automated detection of potential emphysema software; LTA provides visualization and quantification of the lung textures; PHA Analysis, a cutting-edge, fully-automated imaging solution; XV LVAS, a lung airflow imaging software; and XV Scanner, a lung function scanner.
4DMedical Limited Fundamentals Summary
| 4DX fundamental statistics | |
|---|---|
| Market cap | AU$3.36b |
| Earnings (TTM) | -AU$172.93m |
| Revenue (TTM) | AU$5.81m |
Is 4DX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4DX income statement (TTM) | |
|---|---|
| Revenue | AU$5.81m |
| Cost of Revenue | AU$472.45k |
| Gross Profit | AU$5.34m |
| Other Expenses | AU$178.26m |
| Earnings | -AU$172.93m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 91.87% |
| Net Profit Margin | -2,976.16% |
| Debt/Equity Ratio | -22.8% |
How did 4DX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/21 12:18 |
| End of Day Share Price | 2026/04/21 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
4DMedical Limited is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| John Campbell | Jefferies LLC |
| Stephen Blagg | Jefferies LLC |